CB1 Capital Management predicts Cannabis could disrupt the healthcare industry in a big way. The firm's Founding Partner and Chief Investment Officer Todd Harrison explains why he thinks medical marijuana will migrate from state dispensaries, to become medicine prescribed by doctors through insurance in the next decade.
Harrison says the only way the U.S. government would get their hands on the money in this market opportunity is through the FDA. "That's where we think it goes, follow the money," says Harrison.
"This is not so much a trade about commerce, as it is a trade about healthcare," said Harrison. "We think that this is going to migrate towards medicine." One of CB1 Capital Management's holdings GW Pharmaceuticals is up 30 percent over the past three months. Harrison expects this company to publish research showing the efficacy of cannabis treatment this summer.
Nextdoor CEO Nirav Tolia shares how the neighborhood app's redesign aims to inform, connect, and protect communities with smarter features and local insight.
Tim Bohen dives into the 'Trump Trade,' renewed tariffs, waning uncertainty, corporate guidance, and what the Fed’s next move means for traders and markets.
Wall Street icon Peter Tuchman dives into Apex Trader Funding’s partnership with Wall Street Global Trading Academy and what it means for the next-gen trader.
Matthew Frankel, contributing analyst at The Motley Fool, discusses the recent SPAC resurgence, investor interest, and what the data says about their future.
Axios’ Neil Irwin unpacks the political clash as the White House explores legal pathways to dismiss Fed Chair Powell, threatening central bank independence.
Shark attack survivor Paul de Gelder joins us to talk Navy diving, bull sharks, and his wild return in Air Jaws and more during Discovery’s Shark Week!
